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Abstract
Background: Early pregnancy loss can be associated with trophoblast insufficiency and coagulation defects.
Thrombomodulin is an endothelial-associated anticoagulant protein involved in the control of hemostasis and
inflammation at the vascular beds and it’s also a cofactor of the protein C anticoagulant pathway.
Discussion: We evaluate the Thrombomodulin expression in placental tissue from spontaneous recurrent
miscarriage and voluntary abortion as controls. Thrombomodulin mRNA was determined using real-time
quantitative polymerase chain reaction. Reduced expression levels of thrombomodulin were found in recurrent
miscarriage group compared to controls (1.82-fold of reduction), that corresponds to a reduction of 45% (from
control group Delta CT) of thrombomodulin expression in spontaneous miscarriage group respect the control
groups.
Summary: We cannot state at present the exact meaning of a reduced expression of Thrombomodulin in
placental tissue. Further studies are needed to elucidate the biological pathway of this important factor in the
physiopathology of the trophoblast and in reproductive biology.
Background
Thrombomodulin (TM) is a glycoprotein receptor
composed of 559 amino acid residues and expressed
mainly on the endothelial surface of blood vessels and
in the placental syncytiotrophoblast [1]. It is composed
of different structural domains: an N-terminal lectin-
like module, a hydrophobic region, six EGF-like
repeats, a Ser/Thr-rich region, a trans-membrane
region and a short cytoplasmic tail [2]. This glycosy-
lated transmembrane receptor for activated coagulation
Factor IIa [3] in the intact endothelium thrombomodu-
lin forms a complex with thrombin which is responsi-
ble of converting protein C to activated protein C
[1,4,5]. The Thrombomodulin-thrombin complex bal-
ances the substrate specificity of thrombin, erasing its
procoagulant properties, and improving the conversion
of protein C into its activated form [6]. Protein S and
activated protein C cleave in a proteolytic way the acti-
vated coagulation factors Va and VIIIa: all this com-
plex process inactivates the enzymatic complexes that
make coagulation factors Xa and thrombin active. If
the blood coagulation inhibitor Thrombomodulin lacks
from trophoblast cells of the mouse placenta, a fatal
arrest of placental morphogenesis occurs [7], leading
to embryo failure probably due to tissue factor-
initiated activation of the blood coagulation cascade at
the fetus-maternal interface [8]. In addition, TM inte-
grates fibrinolytic and anti-inflammatory responses also
independently by protein C and thrombin. The analysis
of different mouse models has revealed novel and in
part organ-specific functions of TM, most notably in
the vascular bed of the placenta. In these mouse mod-
els, the severity and phenotypic expression of throm-
bosis is highly variable and is dependent on the
interaction with secondary genetic or environmental
modifiers. The mutant mouse strains replicate impor-
tant aspects of thrombophilia and thrombosis in
humans [9].
The functions of TM are exerted in two distinct tis-
sues: in non-endothelial extra-embryonic tissues,
required for proper function of the early placenta, in
embryonic blood vessel endothelium whose absence
causes lethal consumptive coagulopathy [10].
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With this background, we performed a prospective case-
control study measuring the gene expression of throm-
bomodulin in placental tissues from spontaneous recur-
rent miscarriage and voluntary abortion by Real-Time
quantitative PCR to elucidate the role of this factor on
human miscarriage.
Trophoblastic tissue was obtained during surgical
uterine evacuation in 11 women with recurrent miscar-
riage and 20 healthy primiparous pregnant women
undergoing elective termination of pregnancy matched
for gestational age. Recurrent miscarriage was defined as
occurrence of three consecutive spontaneous miscar-
riages before 20 weeks’ gestation [11]. In the group with
recurrent miscarriage were recruited only the patients
with incoming miscarriage (< 12 hours) who were
admitted in hospital for threatened abortion.
All women enrolled were regularly menstruating, with
a cycle length of < 35 days. Clinical details were
recorded for each woman, and only patients who were
certain of their menstrual dates entered the study group.
Specific exclusion criteria for all women enrolled
included conception by assisted reproduction, gesta-
tional diabetes, diabetes mellitus, a history of smoking
and hypertension, proteinuria, renal, cardiovascular
hepatic, and endocrine disease, metabolic disorders, and
current infection or history of all types of infection.
Moreover, according to our internal protocol, enrolled
subjects did not present with thyroid disease, congenital
or acquired thrombophilic disorders, or chromosomal or
other fetal and uterine anomalies.
None of these women had non-obstetric clinical features
of antiphospholipid syndrome (i.e., history of thrombosis,
autoimmune thrombocytopenia, systemic lupus erythema-
tosus, or other autoimmune conditions). All had negative
test results for lupus anticoagulant and fewer than 20 IgG
phospholipid-binding units of anticardiolipin antibodies.
Furthermore, none of the recruited women took any regu-
lar medication, which included antihypertensive drugs or
MgSO4, before and during the experiment, and none of
the control subjects were on oral contraception; only folic
acid (400 μg/day) was taken during pregnancy and diets
were comparable for all groups.
Since in first trimester placenta a number of other cell
types present within the villous stroma such as fibro-
blasts, myofibroblasts, smooth muscle cells, pericytes
and endothelial cells as well as maternal and fetal blood
cells are potential contaminants, the tissues derived by
curettage were characterized using antibodies to cyto-
keratin antibodies specific for the isoform 7 to obtain an
high grade of trophoblast purification [12].
All specimens were snap-frozen in liquid nitrogen and
stored at -80°C until use. The total length of processing
time was less than 10 minutes. The study was per-
formed in accordance with the principles of the Declara-
tion of Helsinki as revised in 2001. The study was
approved by the local ethics committee, and informed
consent was given by all women enrolled in the study.
A piece of the frozen tissue (20-40 mg) was homoge-
nized in lysis buffer, and the total RNA was extracted
with an RNA isolation kit (Promega, Madison, WI).
RNA samples were tested by ultraviolet absorption at
260 nm in order to determine RNA concentration. The
quality and concentration of the RNA samples were
further confirmed by electrophoresis on denaturated 1%
agarose gels. Two micrograms of RNA were reverse
transcribed in a total volume of 25 μl for 60 min at 37°
C with M-MLV Reverse Transcriptase (Promega, Madi-
son, WI) using random nonamers in order to obtain
complementary DNA (cDNA). cDNA was used for real-
time quantitative PCR. To avoid false-positive results
attributable to the amplification of contaminating geno-
mic DNA in the cDNA preparation, the primers were
selected to flank an intron and PCR efficiencies were
tested and found to be close to 1. The following primers
were used: 5’CTCTTCCAGCCTTCCTTCCT-3’ (for-
ward), 5’-AGCACTGTGTTGGCGTACAG-3’ (reverse)
for b-actin, and 5’-TAACGAAGACACAGACTGC-
GATT-3’ (forward) and 5’-ACCTTGACCTCGTGGGC-
TAG 3’ (reverse) for thrombomodulin. The genes were
run in duplicate using SYBR Green chemistry. All sam-
ples, taken from each pregnancy, were tested in tripli-
cate using as reference gene b-actin for data
normalization to correct for variations in RNA quality
and quantity. To increase accuracy of normalization, a
second housekeeping gene (GAPDH) was used. No sig-
nificant differences were observed in thrombomodulin
expression levels with the use of the additional endogen-
ous control. Direct detection of the PCR products was
monitored by measuring the fluorescence produced by
SYBR Green I dye binding to the double-strand DNA
after every cycle. These measurements were then plotted
against cycle numbers. The parameter Ct (threshold
cycle) was defined as the cycle number at which the
first detectable fluorescence signal above the threshold
was observed. The real-time PCR products were also
electrophoresed on 2% agarose gel, and the intensity of
amplicons of expected size was evaluated (Figure 1).
Fold changes in relative gene expression were calculated
by 2
-Δ(ΔCt) where ΔCt = Ct (thrombomodulin) - Ct (b-
actin) and Δ(ΔCt) = mean ΔCt (pathological placentas) -
mean ΔCt (normal placentas). The Mann-Whitney U
test was performed to compare data from control and
pathological placentas. Differences were considered sig-
nificant at p < 0.05. The results were obtained as “fold
changes” in relative gene expression of study group
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Page 2 of 5Figure 1 Real-time PCR analysis. TM and b-actin amplicons from RM (recurrent miscarriage) and C (controls) were analyzed by electrophoresis
on 2% agarose gel.
Figure 2 Thrombomodulin expression is significantly reduced in spontaneous recurrent miscarriage versus control group (p < 0.05).
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ΔCt ± Standard Deviation, Median ΔCt and first and
third Quartile. The two groups were comparable for
maternal age and gestational age, the characteristics of
the patients recruited are reported in the Table 1.
Reduced expression levels of thrombomodulin were
found in recurrent miscarriage group compared to con-
trols (1,82-fold reduction), that corresponds to a
reduction of 45% (from control group ΔCt) of thrombo-
modulin expression in spontaneous miscarriage group
respect the control group (Figure 2).
Thrombomodulin is considered a protein involved in
coagulation, cancer and embryogenesis. The altered coa-
gulation process leads to a precocious placental failure,
but some studies underline that Thrombomodulin has
an anti-inflammatory ability through both protein C
dependent and independent pathways. The activation of
the coagulation cascade may result in a positive-feed-
back loop consisting of thrombin-mediated repression of
Thrombomodulin-dependent protein C activation [13]:
this aspect shows the strict relation between coagulation
and inflammation, two processes that enhance one to
each other leading to the early placental vascular
damage. In pregnancy, fibrinolysis is controlled by the
maternal endothelium and placenta, both of which are
central to the pathogenesis of some obstetric pathologies
[14]. Some works have discussed that plasma Thrombo-
modulin levels might point out placental vascular
endothelial damage reflecting on birthweight [15]. On
the contrary, other studies have focused the attention
on the role of the Thrombomodulin in cell invasivity
and capability to perform intravasation and extravasa-
tion, during local invasion.
In this work we found a reduced expression of
Thrombomodulin in placental tissue of women who
experienced spontaneous recurrent abortion by Real-
Time quantitative PCR.
This result confirms the observations that loss of
function of Thrombomodulin causes early post-implan-
tation embryonic lethality [16], underlying that
Thrombomodulin expression in non-endothelial placen-
tal cells is required for a normal function of the early
placenta. By this hypothesis the absence of Thrombomo-
dulin from blood vessel endothelium may cause exces-
sive activation of the embryonic blood coagulation
system [17]. We cannot state at present the exact mean-
ing of a reduced expression of Thrombomodulin in pla-
cental tissue. Further studies are needed to elucidate the
biological pathway of this important factor in the phy-
siopathology of the trophoblast and in reproductive
biology.
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